(Reuters) -Eli Lilly on Monday said a mid-stage trial of its next-generation obesity drug candidate "triple G" showed that it led to weight loss of up to 24.2% after 48 weeks, surpassing results seen with other weight loss drugs.
The once-weekly injected drug, retatrutide, is part of a class known as incretins designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow stomach emptying and decrease appetite. The new family of drugs has reignited interest in the weight-loss treatment market, which is estimated to reach $100 billion by the end of the decade.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
